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of variation in resource use for coronary artery bypass surgery (CABG) in 
20 New York (NY) hospitals in 1992 (n = 10,080), Patient (pt) level costs, 
exclusive of professional fees, ware calculated using hospital-spacific, de- 
partment cost to charge ratios and were leveled for hospital-specific factors 
(e.g. teaching costs, input casts). Preoperative risk factors were obtained 
from the NY Cardiac Surgery Reporting System. Mean cost and LOS (4- SD) 
were $14,448:1:$8,606 and 13.5 :t: 8.6 days. Pt factors explained 27% of 
variation in cast and 30% in LOS, with 1" resource use associated with 1" 
age, female gender, ,I. ejection fraction, CHF, prior heart surgery and stroke. 
Hieramhtcai modeling revealed that individual hospitals explained 63% of 
r_~idcal variation In cos'., after adjusting for pt factors. The range of predicted 
cost among hospitals for a typical pt (65 year old white male; 3 diseased 
vessels: ejection fraction 50-59%) was $9,000.-$23,000 (see figure). 
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Conclusions: After adjusting for lot risk factors and differences in input 
costs, considerable variation in CABG costs remained among NY hospitals. 
This inter-hospifal variation identities the potential for substantial cost savings 
in some hospitals. 
2:30 
~"~ Validation of a Cllnlcel Prediction Rule for Predicting 
Left Ventricular Funct ion  Pos t  Acute Myocardial  
Infarction in a Communi ty  Hospital Setting 
Ken "robin, Robert Stumol, Daniel Harber, Dean Karavite, Kim Eagle. 
Botstord General Hospital, Farmington Hills, MI; University of Michigan 
Medical Center, Ann Arbor, MI 
Previously, we (KE) reported that if a post myocardial infercti0n patient 
meets four simple clinical and/or ECG criteria, their left ventricular ejection 
fraction (LVEF) is >_ 40% with a positive predictive value of 0.98. These 
criteria were (1) no history of congestive heart failure (CHF), (2) an ECG 
without oither a LBBB, paced rhythm, or left ventdcular hypertrophy (LVH) 
with strain, (3) an index MI that is not an anterior Q-wave, and (4) no 
history of a prior Q-wave MI outside the currant ischemic zone. In order to 
validate this in the community hospital setting, we identified 213 patients 
admitted with the primary discharge diagnosis of acute myocardial infarction 
(AMI) (ICD Code 410.01--410.91 ) between 6/23/93-3/7/95. All patients in the 
study met standard clinical and enzymatic definitions for acute infarction and 
had undergone at least one measure of LVEF such as echocardiography, 
ventricular angiography or gated blood pool scan. Of 213 patients, the clinical 
rule predicted that 83 (39%) would have LVEF > 40%. Of these 83 patients, 
71 had an ejection fraction > to 40=/=, for a positive predictive value of 86%. Of 
the 12 patients that were incorrectly predicted to have preserved LV function, 
67% (6/12) had an index non-Q anterior MI with an average CK peak of 1300 
U/L. 
Conclusion: This simple clinical prediction rule has a positive predictive 
value of 86% when applied in the community hospital setting. It appears that 
patients with extensive anterior non Q-wave MI may be one group where the 
rule is Inaccurate, We believe that when a technology-based assessment of 
left ventdcular function is considered in the post-MI patient, this prediction 
rule may allnw a more cost effective selection of patients for whom the test 
will be es!'edally helpful and that as many as 40% of patients may require 
no tastL~g at all. 
2:45 
[801-~-J-4 Predictors of Increased Length of Stay of Patients 
Undergoing Coronary Intervention Procedures 
Lad Harmll, Robert Piana, Alexander Pedan, Andrew Selwyn, Thomas Lee, 
Igor F. Paiacios. Cardiac Unit, Massachusetts General Hospital, Brigham 
and Women's Hospital (Partners Inc), Harvard Medical School, Boston 
In the present era of health care reform there is a need to decrease cost in 
patients undergoing coronary intervention procedures. Since post-procedure 
length of stay (LOS) is an important determinant of cost, the present study 
was undertaken to determine factors responsible for increased LOS. A total 
of 1646 patients undenvent 1792 coronary interventionai procedures to treat 
2353 lesions at the Massachusetts General Hospital and the Brigham and 
Women's Hospital from 111/94 to 12/31/94. There were 1139 males and 507 
females, mean age 64 ± 12 years. Median LOS was 4 4- 5 days. Demo- 
graphic, comorbid, procedural and post-procedure adverse event variables 
were included in a stepwise multiple linear regression analysis. Independent 
predictors of LOS Include blood transfusion (p = 0.001), elective by-pass 
surgery (CABG) (p = 0.001 ), vascular repair (p = 0.001), hospital acute renal 
failure (p = 0,001), total number of procedures (p = 0.001 ), history of myocar- 
dial Infarction (p = 0.001), ACC/AHA type C lesion intervention (p = 0,001), 
stent utilization (p = 0.001), diabetes mellltus (p = 0.001), emergent CABG (p 
= 0.001 ), evolving myocardial infarction (p = 0.001 ), cerabrovescular disease 
(p = 0.01) and congestive heart failure (p = 0.0t). The R value of the model 
was 0,6. Conclusion: This model demonstrates the complexity of patients 
undergoing coronary interventions and the factors surrounding their process 
of care. Intervention on select predictors offers the opportunity to model LOS, 
decrease cost and improve quality of care. 
3:00 
~ '~ ' l  The Impact of Stress Testing on Subsequent 
Invasive Cardiac Procedures 
David E. Wannberg, Mide A. Kellett, John D. Dickens, David J. Malanka, 
Leonard M. Keitson, Robert B. Keller. Maine Medical Center, Portland ME; 
Maine Medical Assessment Foundation, Augusta, ME 
There has been considerable interest in explaining the variable use of in- 
vasive cardiac procedures, however, the role of stress testing has been 
relatively ignored. Because most patients being evaluated for chest pain 
initially undergo a stress test, we hypothesized that geographic variation 
in Invasive procedures would largely be explained by the vadable use of 
stress testing. Methods: Twelve coronary anglography service areas were 
constructed for Medicare beneficiaries in Northern New England. Age/sex 
adjusted utilization rates were developed for three procedure categories: 
total stress test, coronary angiography and revascutadzation. Total stress 
tests were further stratified into non-imaging and imaging procedures (e.g., 
thallium). Tests done in follow-up to |nvasive procedures were excluded 
(e.g. stress test following revascularizattons). Linear regression was used 
to assess the relationship between procedure categories. Results: A tight 
relationship was found between tctai stress test rates and the rates of sub- 
sequent coronary angiograbhy (R 2 = 0.61, p < 0.005). Most of the variance 
was explained by imaging stress tests (R 2 : 0.50, p < 0.02). A very strong 
relationship was found between coronary angingraphy and revescularization 
(R ~ = 0.82, p < 0.0001 ). Finally, a clear relationship between total stress tests 
and subsequent revescularizstions was also found (R s = 0.55, p < 0.006). 
Conclusiorr.lhe population based rates of diagnostic testing largely explained 
the variance associated with subsequent therapeutic interventions. Our re- 
sults suggest that local testing intensity is an important determinant of the 
vadable use of invasive cardiac procedures. 
3:15 
1"~'~ Cost ve Outcome for Redo Coronary Surgery vs 
Coronary Angioplasty for Clinical Recurrence After 
Coronary Surgery 
William S. Wstntraub, Patrick D. Mauldin, Edmund Becket, Ellis I -  Jones, 
Douglas C, Morris, Spencer B. King lit, Robert A. Guyton, Joseph 
M. Craver. Emory U School of Medicine, Atlanta GA 
Coronary revasculadzstion after prior corenary surgew was studied in 4174 
patients: PTCA in 2613 and redo CABQ in 1561. PTCA patients were more 
often female (20% vs 16%, p = 0,002), fewer had prior myocardial Infamtion 
(MI) (56% vs 62%, p = 0,0003) or congestive failure (9% vs 15%, p < 0.0001 ). 
Patients were similar in age (61 ± 10), hypertension (48%), diabetes (22%) 
PTCA Redo CABG P Value 
tn Hospits! 
Mortality ~.2Yo 6.8% <0.0001 
Stroke 0% 2.8% 0,27 
Myocardial Infarction 1,5% 5.4% <0.0001 
Length of Stay (days) 3 ± 4 11 :E 12 <0.0001 
Cost (1000's) $8.5 ~ 7.3 $2.4.2 ± 17,3 <0.0001 
5 Years 
SuNival 80% 76% <0,0001 
Corrected Survival 81% 78% NS 
MI Freedom 79% 80% <0.08 
CABG Freedom 96=/. 74% <0.0001 
PTCA Freeclom 90% 58% <0.0001 
Recurrent Angina 48% 41% 0,0002 
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and m~llna class (75% class Ill or IV). While there was less 3 vessel/lalt main 
in PTCA patients (56% vs 75%, p < 0,0001), ejection fractions were similar. 
Comparison of Results and Costs are shown in the table. 
The initial advantage of PTCA over redo CABG in terms of mortality, and 
myocardial Infarction was largely lost by 5 years. There were more additional 
procedures and moun'ant angina with PTCA. The initial cost advantage 
of PTCA may also be lost because of additional procedures. Choice of 
procedure should be made by careful clinical assessment, as a choice of 
therapy to minimize cost is unclear and cannot be justified. 
Calcium Blockers and Other Drug Therapy in 
Acute Myocard ia l  In fa rc t ion  
Wednesday,  March 27, 1996, 4:00 p.m.--5:00 p.m. 
Orange County  Convent ion Center, Room 315 
4:00 
~'~ Hearlt Rate-Lowering Calcium Channel Blockers 
(Dlltiazem, Verapamli) Do Not Adversely Affect 
Long-Term Cardiac Death or  Non-Fatal Infarction in 
Post-lntar~tlon Patlents: Data Pooled From 3 
Randomlzed, Placebo-Contro!led Cllnlcal Trials o f  
5,677 Palfents 
William E. Beden, Franz H. Messedi, Jergan Fischer Hansen, Kenneth 
B. Schechtman. Boston VA. Medical Center, Boston, MA 
Recent meta-analyses and case-control studies purport to show harm as- 
sociated with the use of short-acting calcium channel blockers (CCB)--- 
particuiarly dihydropyddines--io beth hypertensive and ischemio patient sub- 
sets, and cite the absence of evidence-based medicine ragmding long-term 
safety and efficacy. Reports which impugn CCB use are predicated on ret- 
respecllve, non-randomized, unbllnded ata sources with inherent treatment 
biases, and utilize pooled data of divergent CCB agents which may either io- 
crease (dibydropyrldinas) or decrease (diltiazem/verapamil) heart rata (HR). 
We performed a pest h0c analysis of pooled data obtained from 5,677 post- 
MI patients randomized to a HR.iowedng CCB or placebo (P) in the first 
and second Danish Verapamif Infamtion Tdals (DAVIT h n = 1,436; DAVff-II: 
n = 1,775) and the Multicanter Diltiazem Poet-Infarction Tdal (MDPi'r: n = 
2,4¢36). Dudng a mean follow-up of 550 ± 376 days, the combined clinical 
evnot (cardiac death [CD] or MZ) rate was 18% In the CCB group (515/2,827) 
vs, 20=/0 in the P group (582/2,349), p = 0.018 (Kaplan-Maler comparisons; 
generalized Wiiooxon test). Actuarial evant-free survival (CCB vs P groups, 
respectively) was 0.89 vs. 0,87 at 6 mo, 0.85 vs. 0.82 at 12 too, 0.79 vs. 0.77 
at 24 too, and 0.72 vs. 0.69 at 48 mo. After adjusting for relevant covadatas 
(age, gender, diabetes, pdor MI, hypertension) using Cox regression analy- 
ses, HR-iowenng CCBa were associated with significantly reduced CD or MI 
rates (CCB vs P dsk ratio [95% Cl] = 0.88 [0 77-0.99], p = 0,035). 
Conclusions: 1 ) HR-Iowedng CCBs do not increase cardiac events in post- 
MI pts dudng long-term follow-up; 2) such pooled data from randomized, 
double-blind, placebo-controlled trials underscore the importance of differen- 
tiating CCB agents which raise or lower heart rate. 
4:15 
~8"0"~ Long-Term Safety of  Cal©ium Antagonists: 
Reassessment o l the  Furberg Hypothesle 
Franz H. Messedl, Uonel H. Opie, Richard Chambers. Ochsner Meal/ca/ 
Institutions, New Orleans, LA; C, apatown, South Africa 
In ;1 recent mate-analysis, Fu¢cerg et al (Circulation, Sept. 1, 1995) I~zve 
purported to show a dose-related Increase in mortality with short-acting 
nifedlpine In patients with acute myocardial infarction, Since there were sev- 
eral misquotation errors (e.g., dose, total number of patients) when compared 
with the .original publications, we recalculated the mete-analysis in two In- 
dependent statistical centers. Whether a study dealing with stable coronary 
artery disease (INTACT) should be included In a mote-analysis on unstable 
angina and acute myocardial infarction is controversial. Hence, we present 
the data with and without INTACT. 
Results were as follows: 
Source Nifedlplne Control RR (95% CI) P' 
death~pts deaths/pts 
Fud0erg at el., Circulation 335/4171 274/4183 1.16 (1.01-1.33) 0.01 
Furberg et el., recak:ulsted 390/5301 339/5329 1.16 (1.00-1.34) 0.05 
Originals (with INTACT) 320/5109 291/5160 1.11 (0.94-.1.32) 0.19 
Originals (without INTACT) 308/4895 289/4949 1.08 (0.91-1.28) 0.36 
*Chi square test for listed proportions for comparison only. 
Conclusion: The mete-analysis of Furberg at al is incorrect; there is no 
overall significant increase in mortality in the nifedipine group compared with 
the control group. Logistic regression analysis showed neither a group nor a 
dose rciationshtp to mortality. Although the observed increase in mortality in 
the nifedipina group was not statistically significant, our data do not dispute 
the common clinical contention that acute release nifedipine should not be 
used in acute myocardial infarction. 
4:30 
8~"3- -1  Prognosia of  Diabetic Patients After Myocardial 
Infarction: Effect o f  Early Treatment With 
ACE-Inhlbitars 
Giullo Zuanatti, Roberto Latini, Aldo P. Maggioni, Luigi Santoro, 
MariaGrazia Franzosi, Gianoi Tognoni, on behalf of the GISSI-3 
Invasf~ors. ANMCO and Istituto M. Negri, Italy 
It is recognized that diabetic pts have ;1 higher morbidity and mortality after 
myocardial infarction (MI). The effect of novel therapeutic strategies including 
ACE-inhibitors (ACE-0 in these pts is unknown. We analyzed the effect of 
an early treatment with llslnopdl (L) in an unselected population of diabetic 
pts wi~ acute MI enrolled in the GISSI-3 study. L (5 mg up to 10 mg) was 
started within 24 hrs from the onset of symptoms. A total of 2790 pts had 
;1 history of defined diabetes, with clinical and demographic harastadstics 
balanced between groups of treatmanL The 6-week mortality of pts with 
;z history of non-insulin (NIDD) and insulin dependent (IDD) diabetes was 
markedly reduced by L as shown in the table. 
NIDD IDD 
No-L L No-L 
n. of pts 1164 1130 242 254 
mortal'try 10.5% 7.7% 21.1% 11.8% 
% reduction -26.7% -44.1% 
OR (95% el) 0.71 (0.54-0.95) 0.51 (0.31.-0.81) 
The treats~aflt was associated with an increased incidence of in-hospital 
persistent hypotonsion (6.5 vs 4.3% in NIDD, p < 0.05 and 9.1 vs ¢5°/= in 
IDD, pNS) and renal dysfunction (3.2 vs 1,4% in NIDD, p < 0.01 and 3.9 vs 
1.6°/o in IDD p Ns), similar to that observed in non-diabetic pts. 
In conclusion, (1) in diabetic pts with acute MI early treatment with lisinopdl 
is associated with ;1 markedly reduced 6-week mortality (2) the beneficial 
effect is evident in beth NID and ID diabetes.,. 
If confirmed in other studies, these data would support a widespread and 
early use of ACE-i in diabetic pta with acute MI. 
4:45 
[ " ~  Carvedilol Prevents Rem.........~det!!~ and Improves 
Prognosis in Patients With Left Ventdcuiar 
Dysfunction Fol lowing Acute Myocardial Infarction 
Roxy Senior, Sumit Bas'J, Avijit Lahid. Northwk~ Park Hospital, Harrow, UK 
Left vantdcutar (LV) dysfunction following acute myocardial infarction (AMZ) 
affects prognosis advemely possibly due to LV remodelling. Carvediiol (C) is 
a multiple acting, non-selsotive ~-blocker with additional vasodiiatory prop- 
er~as. To assess the role of C on LV remodalllag and its effect on prognosis 
(adverse cardiac events) 49 consecutive patients (pto) with LV ejection free- 
,on < 45% (34 ± 8%, moan 4- SD) following AMI were evaluated in a 
double-blind, randomised, placebo (P) controlled study. [=Is received medi- 
cation immediately following thrembolysis and continued for 6 months dudng 
which they were followed up. 2D Echoca~hy (Echo) was per~nned at 
p re -d~ 0/1) (8-.10 days) and at 3 months 0/2). Parametam evaluated 
were: LV ejection fraction (LVEF)%, end-systolic (ESV) and end-cr~'tdiio 
volumes (EOV) (mis), wall motion score index 0NMSI) and regional (site of 
infarct) wall motion score (RWMS). Wall motion score was graded from 0 
(normal) to 4 (dysldnstio). Analysis of variance was performed. 
ESV EDV WMSI RWMS 
Vl V2 V1 V2 Vl V2 V1 V2 
C 78±22 74:1:30 121±29 122+34 1.44-0.5 1.0±0.7 124-3 84-4 
P 914-32 1004-47 1374-38 1484-54 1.6:E0.4 1.44-0.6 134-3 11:1:5 
p value 0.01 0.01 0.03 0.0~ 
There were significantly less cardiac events (p = 0.04) with C (21%) 
compared to P (52%). Thus, C prevented LV remodelling and improved 
prognosis in pts with AMI and LV dysfunction. 
